Introduction
============

At present, transplantation is the best treatment for end-stage renal disease. Survival and quality of life among transplant patients are significantly better than in dialysis patients ([@b1-mmr-22-03-2329]). Despite the routine use of immunosuppressive therapies in the care of post-transplant patients, acute rejection (AR) of the renal allograft still occurs. Sensitive and early detection of AR episodes in patients with renal transplant is essential to preserve allograft function. The majority of patients with AR are asymptomatic and the detection of AR critically relies on regular monitoring for increases in serum creatinine, an insensitive laboratory biomarker of renal injury, as a sign of renal hypofunction ([@b2-mmr-22-03-2329],[@b3-mmr-22-03-2329]). The current best practice for diagnosis of AR is renal biopsy, but this is invasive, time-consuming, costly and inconvenient. Therefore, noninvasive and sensitive methods would be valuable for the early detection of AR.

Biomarkers may be used for noninvasive prediction or diagnosis of AR in patients with kidney transplantation ([@b4-mmr-22-03-2329]). Suitable candidate biomarker(s) should be based on a simple and cost-effective assay, requiring the noninvasive collection of a test sample, yet it should be specific and sensitive, as the results may prolong graft survival and improve patient health. Proteomics have been widely employed in numerous fields of medical research ([@b5-mmr-22-03-2329]--[@b7-mmr-22-03-2329]). It is an interdisciplinary area for the discovery of candidate biomarkers that may be applied for noninvasive diagnoses.

Isobaric tags for relative and absolute quantitation (iTRAQ) is a multiplexed protein quantitative mass spectrometry (MS) technology based on isobaric reagents ([@b8-mmr-22-03-2329]). It may be used to measure eight samples in one experiment ([@b9-mmr-22-03-2329]). The iTRAQ reagent consists of a reporter group, a balance group and a peptide reactive group (PRG) ([@b8-mmr-22-03-2329]). The reporter group ions that are generated appear as peaks in the low-mass region (113, 114, 115, 116, 117, 118, 119 and 121 Da) ([@b10-mmr-22-03-2329],[@b11-mmr-22-03-2329]). As this region is free of other common fragment ions, signals found in this region are only due to contributions from the reporter ions from the corresponding labeled sample digests ([@b12-mmr-22-03-2329]). Therefore, the relationships can be quantified by comparing the peak area of one reporter group peak with another. The ratio of one peak area to another represents the relative amount of a given peptide in each of the corresponding sample digests ([@b12-mmr-22-03-2329]). The balance group ensures that an iTRAQ reagent-labeled peptide, whether labeled with iTRAQ reagent 114, 115, 116 or 117, displays at the same mass ([@b12-mmr-22-03-2329]). The PRG covalently links an iTRAQ reagent isobaric tag with each lysine side chain and N-terminal group of a peptide. Multiple peptides in a sample digest are labeled ([@b12-mmr-22-03-2329]). The advantage of iTRAQ is that it allows for concurrent quantization of complex samples but requires only a small amount of sample ([@b13-mmr-22-03-2329]). Previous studies have indicated that quantitative proteomics using iTRAQ technology has the potential for diagnosis and treatment with AR after kidney transplantation ([@b14-mmr-22-03-2329],[@b15-mmr-22-03-2329]). Therefore, the present study performed a quantitative proteomic analysis with an iTRAQ-based liquid chromatography electrospray ionization tandem MS (LC-ESI-MS/MS) approach to detect proteins differentially expressed in the serum of patients with AR and healthy individuals with no kidney transplant. Insight from the present study may help advance the understanding of the pathogenic mechanisms of AR and identify potential novel approaches for early diagnosis of AR.

Materials and methods
=====================

### Serum sample collection

A total of 12 subjects, including patients with AR (1 male and 2 females; age, 51--61 years) and 9 age and gender matched healthy controls (6 males and 3 females; age, 40--55 years) were enrolled in the present study. All healthy controls were enrolled from the Guilin No. 924 Hospital (Guilin, China), with no prior history of chronic disease. Their characteristics are listed in [Table I](#tI-mmr-22-03-2329){ref-type="table"}. The primary disease of the patients with AR was chronic glomerulonephritis. All patients with AR had received hemodialysis for \>2 years prior to kidney transplantation and had no infectious diseases (such as hepatitis or tuberculosis) or autoimmune diseases. All kidney grafts were from donation after cardiac death of the donors and the patients had no history of organ transplantation. All patients with AR received tacrolimus, methylprednisolone and mycophenolate mofetil, to maintain triple immunosuppressive therapy. None of the subjects had a history of smoking or drinking. Serum specimens were collected from the Department of Nephrology at Guilin No. 924 Hospital (Guilin, China) between March and September in 2015. The study was performed in accordance with the Declaration of Helsinki and was approved by the Medical Ethics Committee of Guilin No. 924 Hospital (Guilin, China). Written informed consent was obtained from all participants. The serum samples (5 ml) were collected in serum separator Vacutainer tubes and were separated by centrifugation at 250 × g at 20°C for 10 min. Serum was divided into 0.5-ml aliquots and stored at −80°C until further analysis.

### Protein preparation and tryptic digestion

Serum samples were disrupted in lysis buffer (7 M urea, 2 M thiourea, 0.2% SDS, 20 mM Tris) with enzyme inhibitors (1X protease inhibitor Cocktail, 1 mM EDTA). After centrifuging the mixtures at 25,000 × g at 4°C for 20 min, the supernatants were mixed with 5 volumes of cold acetone and stored at −20°C for 2 h to overnight. The mixtures were centrifuged at 25,000 × g for 20 min at 4°C, and the protein pellets were dissolved with lysis buffer, to which 10 mM dithiothreitol was added, prior to incubation at 56°C for 1 h in order to reduce the disulfide bonds of peptides. Then 55 mM iodoacetamide was added to the solution prior to storage in the dark for 45 min, followed by addition of 5 volumes of chilled acetone and storage at −20°C for 2 h. The solution was centrifuged at 25,000 × g for 20 min at 4°C and the pellet was dissolved with lysis buffer to obtain the protein solution. The protein concentration of the supernatant was determined with the Bradford assay method.

For each sample, 100 µg protein was digested with Trypsin Gold at a ratio of protein/trypsin of 20:1 at 37°C for 4 h. Fresh Trypsin Gold was added with the ratio of protein/trypsin of 20:1 again and the mixture was incubated at 37°C for an additional 8 h.

### iTRAQ labelling and peptide fractionation

The peptides were vacuum centrifuged to dryness after trypsin digestion. The product was redissolved with 0.5 M triethylammonium bicarbonate and the iTRAQ labelling of peptide samples was performed using iTRAQ Reagent 8-plex kit (AB SCIEX) in accordance with the manufacturer\'s protocol. The peptides of the healthy controls were labelled with iTRAQ-113 isobaric tags and those from patients with AR with iTRAQ-121 isobaric tags and incubated for 2 h at 20°C. The iTRAQ-labelled peptides were fractionated using reversed-phase (RP) chromatography.

For RP chromatography using a Shimadzu LC-20AB HPLC Pump system (Shimadzu Corp.), 100 µg digested peptides were reconstituted with 2 ml buffer A \[5% acetonitrile (ACN), 95% H~2~O, adjusted to pH 9.8 with ammonia\] and loaded onto a 4.6×250 mm Gemini C~18~ column containing 5-µm particles (Phenomenex Inc.). The peptides were eluted at 20°C at a flow rate of 1 ml/min with a gradient of 5% buffer B (5% H~2~O, 95% ACN, adjusted to 9.8 with ammonia) for 10 min, followed by a 5--35% buffer B gradient for 40 min and a 35--95% buffer B gradient for 1 min. The system was maintained in 95% buffer B for 3 min, which was switched to 5% within 1 min prior to equilibrating with 5% buffer B for 10 min. Elution was monitored by measuring the absorbance at 214 nm and a different vial was used every min. The eluted peptides in 20 fractions were pooled and vacuum-dried.

### LC-ESI-MS/MS analysis

Each fraction was resuspended in buffer A \[5% ACN, 0.1% formic acid (FA)\] and centrifuged at 20,000 × g for 10 min at 4°C, and the final concentration of peptides was \~0.5 g/l. The supernatant was loaded on a LC-20AD nanoHPLC (Shimadzu Corp.) by an autosampler onto a 2-cm C~18~ trap column. The peptides were purified using an 18-cm analytical C~18~ column (inner diameter 75 µm, packed in-house). The samples were loaded and elution was performed in the following order: 8 µl/min for 4 min, 41 min gradient running at 300 nl/min from 5 to 35% B (95% ACN, 0.1% FA), 5 min linear gradient to 80% buffer B (maintained for 5 min), followed by a return to 5% within 1 min.

Data acquisition was performed with a TripleTOF 5600 System (AB SCIEX) fitted with a Nanospray III source (AB SCIEX) and a pulled quartz tip as the emitter (New Objectives), and controlled with Analyst 1.6 software (AB SCIEX). Data were acquired under the following MS conditions: Ion spray voltage, 2.5 kV; curtain gas, 30 psi; nebulizer gas, 15 psi; and interface heater temperature, 150°C. The resolution was \~30,000. For information-dependent acquisition, survey scans were acquired at 250 msec and 30 production scans were collected if exceeding a threshold of 120 counts/sec and with a 2+ to 5+ charge state. The total cycle time was set to 3.3 sec. The Q2 transmission window was 100 Da for 100%. A total of four time bins for each scan was performed at a pulse frequency value of 11 kHz through monitoring of the 40 GHz multichannel TDC detector with four-anode channel detection. An iTRAQ adjust rolling collision energy was applied to all precursor ions for collision-induced dissociation. The dynamic exclusion set for 1/2 of peak width (15 sec).

### Proteomics data analysis

After separating the peptides, identification and quantification of detected proteins were performed. The MS/MS spectra were searched using Mascot software (version 2.3.02; Matrix Science, Ltd.). For protein identification, the search parameters were as follows: Fragment mass tolerance of 0.1 Da, peptide mass tolerance of 0.05 Da, MS/MS Ion as the type of search, trypsin as the enzyme, mass values of monoisotopic, variable modifications of iTRAQ8plex (Y) and oxidation (M), fixed modifications of iTRAQ8plex (K), iTRAQ8plex (N-term) and carbamidomethyl (C) and database of human201512 (132,191 sequences). Protein identifications were considered reliable if they involved at least one unique peptide. An automated software called IQuant ([@b16-mmr-22-03-2329]) was used for quantitatively analyzing the labeled peptides with isobaric tags. It integrates Mascot Percolator ([@b17-mmr-22-03-2329]) and advanced statistical algorithms to process the MS/MS signals generated from the peptides labeled by isobaric tags. The main IQuant quantitation parameters were as follows: Quant_peptide of all unique peptides, Quant_number of at least one unique spectrum, Variance stabilization normalization, Protein_Ratio of weighted average and permutation tests as Statistical Analysis. High-confidence peptide identification was obtained by setting a false discovery rate of \<1% at the peptide level. At least one unique peptide per protein group was required for identification of proteins and two quantified peptides for quantification of proteins. Functional enrichment analysis was performed using the Clusters of Orthologous Groups of proteins (COGs) (<https://www.ncbi.nlm.nih.gov/COG>) and the Gene Ontology (GO) (<http://www.geneontology.org/>) database. Pathway analysis was also performed by Kyoto Encyclopedia of Genes and Genomes (KEGG) mapping (<http://www.genome.jp/kegg/>). For biological pathway analysis and GO term enrichment, P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Protein identification and quantification

Using Mascot Percolator ([@b17-mmr-22-03-2329]), 1,399 proteins were identified and quantified with the cutoff of Q≤0.01 ([Table SI](#SD1-mmr-22-03-2329){ref-type="supplementary-material"}). A total of 604 identified proteins contained \>1 peptide, including 259 proteins with ≥5 peptides, 63 proteins with 4 peptides, 95 proteins with 3 peptides and 187 proteins with 2 peptides. Using a strict cut-off of a 1.2-fold change in expression and Q\<0.05, 109 proteins \[including 72 upregulated proteins ([Tables II](#tII-mmr-22-03-2329){ref-type="table"} and [SII](#SD2-mmr-22-03-2329){ref-type="supplementary-material"}) and 37 downregulated proteins ([Tables III](#tIII-mmr-22-03-2329){ref-type="table"} and [SIII](#SD3-mmr-22-03-2329){ref-type="supplementary-material"})\] were found differentially expressed in AR specimens compared with those in the control samples. As presented in [Fig. 1](#f1-mmr-22-03-2329){ref-type="fig"}, a volcano plot of the log2 fold-change (x-axis) vs. -log10 Q-value (y-axis) was used to depict the differentially expressed proteins (DEPs).

### Gene ontology analysis

These DEPs were analyzed by GO annotation and categorized into 'molecular function', 'cellular component' and 'biological process'. 'Molecular function' describes activities, such as catalysis or binding, that occur at the molecular level. In this category, the proteins were indicated to be involved in 16 terms, including binding activity (48.95%), catalytic activity (27.27%), enzyme regulator activity (5.85%) and structural molecule activity (4.03%; [Fig. 2A](#f2-mmr-22-03-2329){ref-type="fig"}). In the category 'cellular component', the proteins were enriched in 16 terms and the majority of them were located in the cell part (17.43%), cell (17.43%), organelle (12.96%) and organelle part (9.60%; [Fig. 2B](#f2-mmr-22-03-2329){ref-type="fig"}). In the category 'biological process', 23 terms were enriched, with 10.68% of the proteins participating in the cellular process, followed by single-organism process (9.82%), metabolic process (9.61%) and biological regulation (8.10%; [Fig. 2C](#f2-mmr-22-03-2329){ref-type="fig"}).

### COG analysis

COGs were delineated by comparing protein sequences encoded in complete genomes, representing major phylogenetic lineages. COGs comprise a framework for functional and evolutionary genome analysis. In the analysis of COGs, all identified proteins were classified into 23 functional categories ([Table IV](#tIV-mmr-22-03-2329){ref-type="table"}), including posttranslational modification, protein turnover, chaperones (149 proteins, 20.67%), general function prediction only (119 proteins, 16.50%), energy production and conversion (56 proteins, 7.77%) and signal transduction mechanisms (47 proteins, 6.52%).

### Pathway enrichment analysis

The KEGG database was used to identify the pathways in which the DEPs were involved. The results indicated that of these proteins were accumulated in 290 different pathways. The majority of the proteins were involved in 'Complement and coagulation cascades' (30 proteins, 18.18%), '*Staphylococcus aureus* infection' (23 proteins, 13.94%), 'Systemic lupus erythematosus' (22 proteins, 13.33%) and 'Amoebiasis' (21 proteins, 12.73%). The top 30 DEPs in the KEGG pathway enrichment are presented in [Table V](#tV-mmr-22-03-2329){ref-type="table"}. Protein interactions have an important role in certain biological functions, including immune response, blood coagulation, inflammatory response, ion homeostasis, cholesterol metabolism, actin binding, cell motility, energy metabolism, RNA post-transcriptional modification, amino acid metabolism, small molecule biochemistry, cellular growth and proliferation ([@b18-mmr-22-03-2329]--[@b21-mmr-22-03-2329]). A pathway enrichment analysis of DEPs was implemented based on the KEGG database in AR patients and healthy controls ([Fig. 3](#f3-mmr-22-03-2329){ref-type="fig"}). All abbreviations are shown in [Table SIV](#SD4-mmr-22-03-2329){ref-type="supplementary-material"}.

Discussion
==========

The major impediment to success in kidney graft is acute graft rejection, which leads to loss of the organ occur mainly in the first year after transplantation ([@b22-mmr-22-03-2329]). The lack of applicable biomarkers to predict rejection is the biggest challenge in AR. Renal biopsy offers an accurate detection method for AR but the invasiveness of this procedure and other adverse effects may limit its use in certain patients ([@b23-mmr-22-03-2329]--[@b25-mmr-22-03-2329]). Therefore, the reliable and timely identification of potential early biomarkers for rejection is essential. A number of studies have been performed over the past decade ([@b26-mmr-22-03-2329]--[@b29-mmr-22-03-2329]); the majority of them depend on the combination of stable isotopes for obtaining mass spectrometric ordering and relative quantification ([@b30-mmr-22-03-2329],[@b31-mmr-22-03-2329]). Of these, iTRAQ technology, which is based on the labelling of peptides in up to 8 proteomes at the MS/MS level for relative and absolute quantization, is the most widely used for numerous types of diseases ([@b18-mmr-22-03-2329]--[@b20-mmr-22-03-2329],[@b32-mmr-22-03-2329]--[@b34-mmr-22-03-2329]). Wu *et al* ([@b14-mmr-22-03-2329]) used iTRAQ technology to detect DEPs in the plasma of patients with acute renal allograft rejection. The results demonstrated that NF-κB, and signal transducer and activator of transcription 1 and 3, are potential markers for AR and may lead to novel strategies for diagnosis and treatment. Freue *et al* ([@b15-mmr-22-03-2329]) quantitated the relative plasma concentrations of proteins in patients with acute renal allograft rejection by using iTRAQ labeling and quantitative proteomic technology. The study indicated that the profiling of the plasma proteome provided a promising method to monitor the immunological course in patients with AR following renal allograft. The present study performed a proteomics analysis using iTRAQ technology and several proteins were identified as potential candidate biomarkers for the accurate diagnosis of AR. In the present study, 109 proteins with a fold change ≥1.2 were identified, 72 of which were upregulated and 37 were downregulated. GO analysis in the category 'biological process' revealed that alterations in the expression of identified proteins in patients with AR were involved in diverse biological processes, including a single-organism process, cellular process, biological regulation and metabolic process, confirming that the pathogenesis of AR is associated with different molecular mechanisms. Some of these proteins, including properdin and keratin 1 (KRT1), may have the potential to be used as a serum biomarker in the diagnosis of AR.

Complement proteins have an important role in the ischemia/reperfusion injury (IRI) ([@b35-mmr-22-03-2329]), which prominently contributes to morbidity and mortality in acute renal allograft failure ([@b36-mmr-22-03-2329]). Properdin is a γ-globulin protein made up of multiple identical monomeric subunits and is a stabilizer of surface-bound C3bBb. It facilitates the complement alternative pathway for C3-convertase formation ([@b37-mmr-22-03-2329]). Properdin is the only known positive regulator of complement activation ([@b38-mmr-22-03-2329]). Miwa *et al* ([@b39-mmr-22-03-2329]) suggested that properdin has a major pathogenic role during early renal IRI and anti-properdin therapy may have a beneficial effect in human IRI. Consistent with the literature, properdin was also significantly upregulated in the serum of patients with AR in the present study. According to these results, it may be hypothesized that high levels of properdin may be significantly involved in the development of AR. However, its specific roles in AR have not been well studied and require to be further investigated.

Another significantly upregulated protein in AR identified in the present study was KRT1, which belongs to the keratin family. KRT1 is polymorphic ([@b40-mmr-22-03-2329]) and has been reported to be expressed in endothelial cells ([@b41-mmr-22-03-2329]). KRT1 is involved in the lectin complement pathway caused by oxidative stress in endothelial cells ([@b42-mmr-22-03-2329]). Transplant recipients may have antibodies to endothelial cells ([@b43-mmr-22-03-2329]--[@b47-mmr-22-03-2329]). Guo *et al* ([@b48-mmr-22-03-2329]) indicated that KRT1 antibodies were probably autoantibodies and the presence of KRT1 antibodies is significantly associated with deterioration of kidney allograft function. Analysis of the LC-ESI-MS/MS data indicated that KRT1 was differentially expressed between AR patients and healthy controls. This protein may be a valuable diagnostic marker for monitoring patients\' conditions but its possible role in allograft rejection requires further investigation.

In addition, certain novel candidate protein markers identified in the present study, including lipoprotein (a) \[Lp(a)\] and vitamin D-binding protein (VDBP), were significantly upregulated between AR patients and healthy controls. Previous studies have revealed that Lp(a) promotes atherosclerotic diseases, including stroke and coronary heart disease ([@b49-mmr-22-03-2329],[@b50-mmr-22-03-2329]). Shimoyamada *et al* ([@b51-mmr-22-03-2329]) reported that smooth muscle cell proliferation could be induced by Lp(a) as a mechanism of atherosclerosis in the rejected kidney. The deposition of Lp(a) in lesions in vascular rejection of transplanted kidneys is similar to that in atherosclerotic lesions. VDBP is a multifunctional protein ([@b52-mmr-22-03-2329],[@b53-mmr-22-03-2329]) that occurs in serum, cerebrospinal fluid and ascitic fluid, and is characterized as being capable of binding various forms of vitamin D ([@b54-mmr-22-03-2329]). 1,25-dihydroxycholecalciferol \[1,25-(OH)~2~D~3~; also known as calcitriol\] is one of the active forms of vitamin D in the kidney. Previous studies have revealed that 1,25-(OH)~2~D~3~ has an essential role in immunoregulation and allograft rejection ([@b55-mmr-22-03-2329],[@b56-mmr-22-03-2329]), and VDBP may be one of the serum biomarker candidates of acute renal allograft rejection. These candidate proteins may provide a scientific foundation for the pathogenic mechanisms and potential therapeutic approach for AR that warrant further research.

The proteins identified as differentially expressed in patients with AR may be involved in the process of AR and have an important role in the development of the condition. In this study, the healthy controls were healthy individuals with no kidney transplant. Patients with kidney transplant but no AR were not included in the control group because these patients had other health conditions that were unsuitable for the control group. In future studies, it would be ideal to collect adequate specimens from patients with kidney transplant but no AR and with no other health conditions. One limitation of the present study was the small population due to AR being rare in the clinic and the number of patients with AR that met the selection requirements being small. The low sample numbers limit the ability to classify stages of acute renal allograft rejection. Due to the small sample size, it was not possible to determine the correlations of the levels of DEPs with multifarious risk factors or with a specific immune response in detail. If the number of samples was to be increased, different stages of acute renal allograft rejection would be able to be observed, different factors such as gender or age would be considered, and a more objective evaluation could be made for the iTRAQ labelling technique in acute renal allograft rejection. In addition, further validation studies are required to elucidate the mechanisms of the DEPs involved in the biological processes of acute renal allograft rejection, facilitating the development of novel biomarkers for rejection. Therefore, increasing the number of samples will be necessary in further research to obtain more objective and reliable results.

In conclusion, iTRAQ combined with LC-ESI-MS/MS has proven to be a potential and efficient quantitative proteomic technique. The iTRAQ labelling technique was applied to explore the pathogenic mechanisms of AR. The results proved that different protein profile alternations and different pathways were involved in AR. Certain representative candidates, including properdin, KRT1, Lp(a) and VDBP, may serve as potential and novel biomarkers for the early detection of AR.
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###### 

Basic characteristics of patients and healthy controls.

  Characteristic                                                                                                        Patients with acute rejection (n=3)   Healthy controls (n=9)
  --------------------------------------------------------------------------------------------------------------------- ------------------------------------- ------------------------
  Gender (male/female)                                                                                                  1/2                                   7/2
  Age (years)                                                                                                           53.0±7.2                              47.3±5.3
  Serum creatinine (µmol/l) (42--130 µmol/l^[a](#tfn1-mmr-22-03-2329){ref-type="table-fn"}^)                            222.7±82.5                            89.4±10.3
  Blood urea nitrogen (mmol/l) (2.5-8.2 mmol/l^[a](#tfn1-mmr-22-03-2329){ref-type="table-fn"}^)                         20.3±4.9                              4.6±0.8
  Uric acid (µmol/l) (male, 208--440 mmol/l; female, 155--360 mmol/l^[a](#tfn1-mmr-22-03-2329){ref-type="table-fn"}^)   410.7±81.3                            346.0±84.7

The normal ranges.

###### 

Upregulated proteins in patients with acute rejection and control subjects.

  Protein      Description                                                                                                     Protein coverage (%)   Unique peptides   Q-value
  ------------ --------------------------------------------------------------------------------------------------------------- ---------------------- ----------------- ---------
  P35908       Keratin, type II cytoskeletal 2 epidermal                                                                       22.8                   9                 0.004
  P02741       C-reactive protein                                                                                              43.3                   9                 0.001
  Q14520       Hyaluronan-binding protein 2                                                                                    19.6                   10                0.001
  P27918       Properdin                                                                                                       25.4                   8                 0.001
  Q7L523       Ras-related GTP-binding protein A                                                                               1.9                    1                 0.001
  Q53G71       Calreticulin variant (fragment)                                                                                 35.2                   10                0.001
  P10645       Chromogranin-A                                                                                                  9.4                    1                 0.001
  Q1HP67       Lipoprotein, Lp(A)                                                                                              6.2                    10                0.001
  B4DUV1       Fibulin-1                                                                                                       40.1                   7                 0.001
  K7ER74       Protein APOC4-APOC2                                                                                             55.6                   5                 0.001
  P12259       Coagulation factor V                                                                                            25.9                   46                0.001
  P08311       Cathepsin G                                                                                                     26.7                   6                 0.001
  P04004       Vitronectin                                                                                                     57.5                   16                0.001
  F5H6X6       Neutral alpha-glucosidase AB                                                                                    14.0                   9                 0.036
  P13645       Keratin, type I cytoskeletal 10                                                                                 35.6                   12                0.001
  P02790       Hemopexin                                                                                                       41.6                   15                0.001
  P69905       Alpha-2 globin chain                                                                                            67.6                   7                 0.001
  Q12794       Hyaluronidase                                                                                                   26.4                   7                 0.001
  P20742       Pregnancy zone protein                                                                                          29.8                   25                0.001
  A0A0C4DH43   Uncharacterized protein (Fragment)                                                                              36.1                   1                 0.007
  H6VRG3       Keratin 1                                                                                                       43.9                   1                 0.001
  P03950       Ribonuclease A A1                                                                                               44.9                   6                 0.001
  P00450       CP protein                                                                                                      49.7                   32                0.001
  D6RF35       Vitamin D-binding protein                                                                                       65.5                   2                 0.004
  P02675       Epididymis secretory sperm binding protein Li 78p                                                               67.2                   22                0.001
  B4E380       Histone H3                                                                                                      11.5                   2                 0.009
  P14618       Pyruvate kinase                                                                                                 46.9                   4                 0.001
  B2RDW0       cDNA, FLJ96792, highly similar to *Homo sapiens* calmodulin 2 (phosphorylase kinase, delta), mRNA               53.0                   5                 0.038
  P00734       Prothrombin                                                                                                     93.2                   36                0.001
  Q5NV62       V3-4 protein (fragment)                                                                                         18.2                   1                 0.001
  P01008       Serpin peptidase inhibitor, clade C (antithrombin), member 1, isoform CRA_a                                     89.4                   23                0.001
  P02656       Apolipoprotein C-III                                                                                            99.9                   9                 0.001
  P00451       Coagulation factor VIII                                                                                         10.3                   13                0.001
  Q96IY4       Carboxypeptidase B2                                                                                             25.8                   11                0.001
  P61626       C-type lysozyme                                                                                                 52.0                   3                 0.001
  Q8WVW5       Putative uncharacterized protein (fragment)                                                                     65.8                   5                 0.001
  P62805       Histone H4                                                                                                      69.9                   7                 0.001
  Q15113       Procollagen C-endopeptidase enhancer 1                                                                          41.4                   12                0.001
  P34096       Full-length cDNA clone CS0DF032YM23 of fetal brain of *Homo sapiens* (human)                                    55.1                   6                 0.001
  B0YIW1       Apolipoprotein A-V variant 3                                                                                    37.7                   11                0.001
  B2R773       cDNA, FLJ93312, highly similar to *Homo sapiens* adipose most abundant gene transcript 1, mRNA                  19.3                   3                 0.001
  P68871       Hemoglobin, beta                                                                                                84.4                   2                 0.004
  G8JLA2       Myosin light polypeptide 6                                                                                      33.6                   5                 0.002
  P35527       Keratin, type I cytoskeletal 9                                                                                  31.0                   14                0.001
  O00391       Sulfhydryl oxidase 1                                                                                            46.7                   28                0.001
  B2R9V7       Superoxide dismutase \[Cu-Zn\]                                                                                  17.1                   4                 0.001
  F2RM37       Coagulation factor IX                                                                                           32.1                   12                0.001
  P08670       Epididymis luminal protein 113                                                                                  27.3                   8                 0.001
  Q6N095       Putative uncharacterized protein DKFZp686K03196                                                                 37.7                   1                 0.002
  P55056       Apolipoprotein C-IV                                                                                             52.8                   5                 0.001
  P02649       Apolipoprotein E                                                                                                  100                  9                 0.001
  P13798       N-acylaminoacyl-peptide hydrolase, isoform CRA_b                                                                10.2                   7                 0.003
  P23142       Fibulin-1                                                                                                       31.7                   7                 0.001
  B3KRF9       cDNA FLJ34156 fis, clone FCBBF3013266, highly similar to Tsukushi (leucine-rich repeat-containing protein 54)   31.2                   7                 0.037
  Q8NG19       Multi-functional protein MFP                                                                                    33.7                   7                 0.004
  Q86UD1       Out at first protein homolog                                                                                    31.1                   6                 0.001
  C9JEU5       Fibrinogen gamma chain                                                                                          31.5                   2                 0.019
  P20160       Azurocidin                                                                                                      22.3                   5                 0.040
  P55072       Epididymis luminal protein 220                                                                                  33.7                   6                 0.001
  B2RA39       cDNA, FLJ94686, highly similar to *Homo sapiens* complement factor H-related 5, mRNA                            17.6                   9                 0.001
  A0A075B785   LisH domain and HEAT repeat-containing protein KIAA1468                                                         1.2                    1                 0.003
  P02671       Fibrinogen alpha chain                                                                                          30.7                   15                0.003
  P04406       GAPDH                                                                                                           57.0                   14                0.001
  P11586       C-1-tetrahydrofolate synthase, cytoplasmic                                                                      6.1                    5                 0.017
  Q02818       Nucleobindin-1                                                                                                  25.4                   9                 0.006
  P05164       Myeloperoxidase                                                                                                 64.0                   31                0.001
  B3KQ20       cDNA FLJ32635 fis, clone SYNOV2000178, highly similar to Proteoglycan-4                                         34.6                   13                0.001
  A0A024R7F1   Protein kinase C substrate 80K-H, isoform CRA_a                                                                 14.0                   6                 0.007
  H9KV75       Alpha-actinin-1                                                                                                 26.5                   9                 0.001
  B4DWH0       cDNA FLJ55670, highly similar to EGF-containing fibulin-like extracellular matrix protein 1                     42.9                   10                0.001
  Q13103       Secreted phosphoprotein 24                                                                                      32.2                   6                 0.001
  Q9UBX5       Fibulin 5, isoform CRA_b                                                                                        14.1                   6                 0.017

cDNA, complementary DNA; EGF, epidermal growth factor; APOC, apolipoprotein C; CP, ceruloplasmin.

###### 

Downregulated proteins in patients with acute rejection and control subjects.

  Protein      Description                                                                                                                                  Protein coverage (%)   Unique peptides   Q-value
  ------------ -------------------------------------------------------------------------------------------------------------------------------------------- ---------------------- ----------------- ---------
  B4DRV4       cDNA FLJ55667, highly similar to secreted protein acidic and rich in cysteine                                                                44.8                   7                 0.001
  H7C3N9       Leucine-rich repeat flightless-interacting protein 2 (fragment)                                                                              8.2                    1                 0.036
  Q71M29       Putative uncharacterized protein FP3420                                                                                                      4.3                    1                 0.027
  P05109       Protein S100-A8                                                                                                                              11.8                   1                 0.032
  P22792       Carboxypeptidase N subunit 2                                                                                                                 27.2                   11                0.001
  D3JV43       C-X-C motif chemokine (fragment)                                                                                                             35.3                   2                 0.027
  B2R8I2       cDNA, FLJ93914, highly similar to *Homo sapiens* histidine-rich glycoprotein, mRNA                                                           36.0                   2                 0.033
  B4DPP8       cDNA FLJ53075, highly similar to kininogen-1                                                                                                 44.1                   16                0.001
  P02765       Alpha-2-HS-glycoprotein                                                                                                                      39.5                   8                 0.001
  Q6MZL2       Putative uncharacterized protein DKFZp686M0562 (fragment)                                                                                    28.0                   4                 0.001
  P00739       Haptoglobin-related protein                                                                                                                  72.1                   9                 0.016
  P09871       Complement C1s subcomponent                                                                                                                  37.9                   18                0.001
  P06396       Gelsolin                                                                                                                                     35.2                   1                 0.001
  Q9UNU2       Complement protein C4B frameshift mutant (fragment)                                                                                          61.6                   1                 0.038
  P27169       Serum paraoxonase/arylesterase 1                                                                                                             52.1                   11                0.001
  A4D1F6       Leucine-rich repeat and death domain-containing protein 1                                                                                    0.7                    1                 0.017
  P02760       Protein AMBP                                                                                                                                 33.0                   8                 0.001
  F5GXQ5       Glycine N-acyltransferase-like protein 3 (fragment)                                                                                          3.2                    1                 0.001
  O95445       Apolipoprotein M                                                                                                                             60.1                   6                 0.001
  O43866       CD5 antigen-like                                                                                                                             43.5                   13                0.001
  V9H1C1       Gelsolin exon 4 (fragment)                                                                                                                   46.4                   1                 0.017
  F1C4A7       Monocyte differentiation antigen CD14                                                                                                        29.6                   9                 0.020
  P01024       Epididymis secretory sperm binding protein Li 62p                                                                                            87.9                   98                0.001
  Q5T985       Inter-alpha-trypsin inhibitor heavy chain H2                                                                                                 44.4                   31                0.001
  B7Z539       cDNA FLJ56954, highly similar to Inter-alpha-trypsin inhibitor heavy chain H1                                                                49.9                   2                 0.011
  B2R815       cDNA, FLJ93695, highly similar to *Homo sapiens* serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 4, mRNA   37.9                   14                0.001
  A0A0A0MSP7   FERM and PDZ domain-containing protein 3 (fragment)                                                                                          0.3                    1                 0.010
  P80108       Phosphatidylinositol-glycan-specific phospholipase D                                                                                         38.1                   24                0.001
  P02652       Apolipoprotein A-II                                                                                                                          99.9                   8                 0.001
  P51884       Lumican                                                                                                                                      32.2                   9                 0.001
  B4DU16       cDNA FLJ54550, highly similar to *Homo sapiens* fibronectin 1, transcript variant 6, mRNA                                                    78.7                   1                 0.004
  Q96PD5       N-acetylmuramoyl-L-alanine amidase                                                                                                           35.1                   10                0.001
  A0A087WXI2   IgGFc-binding protein                                                                                                                        2.6                    9                 0.010
  P01031       Complement C5                                                                                                                                50.1                   69                0.001
  P15169       Carboxypeptidase N catalytic chain                                                                                                           24.0                   8                 0.010
  A0A024R462   Fibronectin 1, isoform CRA_n                                                                                                                 69.7                   50                0.001
  A8K1K1       cDNA FLJ76342, highly similar to *Homo sapiens* carnosine dipeptidase 1 (metallopeptidase M20 family), mRNA                                  42.8                   17                0.001

cDNA, complementary DNA; AMBP, alpha-1-microglobulin.

###### 

Protein number for each Cluster of Orthologous Groups of proteins function category.

  Code   Functional category                                             Number of proteins
  ------ --------------------------------------------------------------- --------------------
  A      RNA processing and modification                                 1
  B      Chromatin structure and dynamics                                9
  C      Energy production and conversion                                56
  D      Cell cycle control, cell division, chromosome partitioning      19
  E      Amino acid transport and metabolism                             42
  F      Nucleotide transport and metabolism                             20
  G      Carbohydrate transport and metabolism                           37
  H      Coenzyme transport and metabolism                               12
  I      Lipid transport and metabolism                                  23
  J      Translation, ribosomal structure and biogenesis                 26
  K      Transcription                                                   21
  L      Replication, recombination and repair                           22
  M      Cell wall/membrane/envelope biogenesis                          13
  N      Cell motility                                                   4
  O      Posttranslational modification, protein turnover, chaperones    149
  P      Inorganic ion transport and metabolism                          7
  Q      Secondary metabolites biosynthesis, transport and catabolism    15
  R      General function prediction only                                119
  S      Function unknown                                                24
  T      Signal transduction mechanisms                                  47
  U      Intracellular trafficking, secretion, and vesicular transport   9
  Y      Nuclear structure                                               1
  Z      Cytoskeleton                                                    45

###### 

Top 30 DEPs mapped to pathways.

  Pathway                                                 DEPs with pathway annotation   All proteins with pathway annotation   P-value                                                        Pathway ID
  ------------------------------------------------------- ------------------------------ -------------------------------------- -------------------------------------------------------------- ------------
  Complement and coagulation cascades                     30 (18.18)                     86 (6.63)                              2.940498e-08^[a](#tfn4-mmr-22-03-2329){ref-type="table-fn"}^   ko04610
  Osteoclast differentiation                              11 (6.67)                      39 (3.00)                              0.006834358^[a](#tfn4-mmr-22-03-2329){ref-type="table-fn"}^    ko04380
  Thyroid hormone signaling pathway                       11 (6.67)                      43 (3.31)                              0.01483172^[a](#tfn4-mmr-22-03-2329){ref-type="table-fn"}^     ko04919
  Pertussis                                               18 (10.91)                     85 (6.55)                              0.01614457^[a](#tfn4-mmr-22-03-2329){ref-type="table-fn"}^     ko05133
  PPAR signaling pathway                                  6 (3.64)                       20 (1.54)                              0.03239792^[a](#tfn4-mmr-22-03-2329){ref-type="table-fn"}^     ko03320
  ErbB signaling pathway                                  3 (1.82)                       7 (0.54)                               0.04790133^[a](#tfn4-mmr-22-03-2329){ref-type="table-fn"}^     ko04012
  Systemic lupus erythematosus                            22 (13.33)                     125 (9.63)                             0.06066206                                                     ko05322
  Malaria                                                 9 (5.45)                       41 (3.16)                              0.06572233                                                     ko05144
  Salivary secretion                                      3 (1.82)                       8 (0.62)                               0.0696401                                                      ko04970
  VEGF signaling pathway                                  3 (1.82)                       8 (0.62)                               0.0696401                                                      ko04370
  Regulation of actin cytoskeleton                        18 (10.91)                     100 (7.70)                             0.07168303                                                     ko04810
  mTOR signaling pathway                                  2 (1.21)                       4 (0.31)                               0.08102746                                                     ko04150
  Herpes simplex infection                                5 (3.03)                       19 (1.46)                              0.08226199                                                     ko05168
  Chagas disease (American trypanosomiasis)               4 (2.42)                       14 (1.08)                              0.090641                                                       ko05142
  Staphylococcus aureus infection                         23 (13.94)                     139 (10.71)                            0.09910894                                                     ko05150
  Glucagon signaling pathway                              4 (2.42)                       15 (1.16)                              0.1118566                                                      ko04922
  MicroRNAs in cancer                                     10 (6.06)                      52 (4.01)                              0.1129492                                                      ko05206
  Phototransduction - fly                                 2 (1.21)                       5 (0.39)                               0.1239715                                                      ko04745
  Protein export                                          1 (0.61)                       1 (0.08)                               0.1271186                                                      ko03060
  Glycosylphosphatidylinositol(GPI)-anchor biosynthesis   1 (0.61)                       1 (0.08)                               0.1271186                                                      ko00563
  Leukocyte transendothelial migration                    15 (9.09)                      87 (6.70)                              0.1274251                                                      ko04670
  Proteoglycans in cancer                                 15 (9.09)                      88 (6.78)                              0.1370228                                                      ko05205
  Rap1 signaling pathway                                  14 (8.48)                      82 (6.32)                              0.1463614                                                      ko04015
  Amoebiasis                                              21 (12.73)                     132 (10.17)                            0.1525601                                                      ko05146
  Focal adhesion                                          16 (9.70)                      97 (7.47)                              0.1572612                                                      ko04510
  HIF-1 signaling pathway                                 5 (3.03)                       23 (1.77)                              0.1576914                                                      ko04066
  Hippo signaling pathway                                 7 (4.24)                       36 (2.77)                              0.1626743                                                      ko04390
  Renin secretion                                         2 (1.21)                       6 (0.46)                               0.1708845                                                      ko04924
  Type II diabetes mellitus                               2 (1.21)                       6 (0.46)                               0.1708845                                                      ko04930
  Renin-angiotensin system                                2 (1.21)                       6 (0.46)                               0.1708845                                                      ko04614

P\<0.05. DEP, differentially expressed protein. Values are expressed as n (%).
